Advertisement

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Ganzini L, Casey DE, Hoffman WF, McCall AL (1993). The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med 153: 1469–75.PubMedCrossRefGoogle Scholar

Literatur

  1. 1.
    Johnson MD, Lavin P, Whetsell WO Jr (1990). Fulminant monophasic multiple sclerosis, Marburg’s type. J Neurol Neurosurg Psychiatry 53(10):918–921.PubMedGoogle Scholar
  2. 2.
    Keegan M, Pineda A, McClelland R (2002) Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 58: 143–146.PubMedGoogle Scholar
  3. 3.
    Mendez MF, Pogacar S (1988). Malignant monophasic multiple sclerosis or „Marburg’s disease“. Neurology 38(7):1153–1155.PubMedGoogle Scholar
  4. 4.
    Poser S, Luer W, Bruhn H, Frahm J, Bruck Y, Felgenhauer K (1992). Acute demyelinating disease. Classification and non-invasive diagnosis. Acta Neurol Scand 86(6):579–585.PubMedGoogle Scholar
  5. 5.
    Rodriguez M, Karnes WE, Bartleson JD et al. (1993) Plasmapheresis in acute episodes of fulminant CNS inflammatory demyelination. Neurology 43:1100–1104.PubMedGoogle Scholar
  6. 6.
    Stoll G, Brück W (2001). Sonderformen der Multiplen Sklerose. In: Zettl UK, Mix E. (Hrsg.) Multiple Sklerose — Kausalorientierte, symptomatische und rehabilitative Therapie. Springer-Verlag, Berlin-New York 81–90.Google Scholar
  7. 7.
    Weinchenker BG (1999). Therapeutic plasma exchange for acute inflammatory demyelinating syndromes of the central nervous system. J Clin Apheresis 14: 144–148.Google Scholar
  8. 8.
    Zettl UK, Lehmitz R, Mix E (2003). Klinische Liquordiagnostik. De Gruyter, Berlin-New York 2003.Google Scholar

Literatur

  1. 1.
    Abele M, Burk K, Schols L et al. (2002) The aetiology of sporadic adult-onset ataxia. Brain 125: 961–968.PubMedCrossRefGoogle Scholar
  2. 2.
    Harding AE (1981). „Idiopathic“ late onset cerebellar ataxia. A clinical and genetic study of 36 cases. J Neurol Sci 51: 259–271.PubMedCrossRefGoogle Scholar

Literatur

  1. 1.
    Kimura J (1989) Electrodiagnosis in diseases of nerve and muscle: principles and practice. F.A. Davis Company, Philadelphia.Google Scholar

Literatur

  1. 1.
    Kortmann RD, Kuhl J, Timmermann B et al. (2000) Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT’ 91. Int J Radiat Oncol Biol Phys 15:269–79.Google Scholar
  2. 2.
    Bode U, Fleischhack G (1998). Tumoren des Nervensystems im Kindesalter. In: Schlegel U, Westphal M (Hrsg.) Neuroonkologie. Thieme, Stuttgart New York. 342–375.Google Scholar
  3. 3.
    Chang CH, Housepian EM, Herbert C Jr. (1969). An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology 93:1351–9.PubMedGoogle Scholar

Literatur

  1. 1.
    Safa G, Joly P, Boullie MC, Thomine E, Lauret P (1995) Melkersson-Rosenthal syndrome treated by thalidomide. Two cases. Ann Dermatol Venereol 122: 609–611.PubMedGoogle Scholar
  2. 2.
    Stein SL, Mancini AJ (1999) Melkersson-Rosenthal syndrome in childhood: successful management with combination steroid and minocycline therapy. J Am Acad Dermatol 41:746–748.PubMedCrossRefGoogle Scholar
  3. 3.
    Sussman GL, Yang WH, Steinberg S (1992) Melkersson-Rosenthal syndrome; clinical, pathologic, and therapeutic considerations. Ann Allergy 69: 187–194.PubMedGoogle Scholar

Literatur

  1. 1.
    Tsukada T, Yamaguchi K, Kameya T (2001). The MEN1 Gene and Associated Diseases: An Update. Endocr Pathol 12:259–273.PubMedCrossRefGoogle Scholar
  2. 2.
    Kato H, Uchimura I, Morohoshi M et al. (1996) Multiple endocrine neoplasia type 1 associated with spinal ependymoma. Intern Med 35:285–9.PubMedGoogle Scholar

Literatur

  1. 1.
    Pareschi R et al. Posterior fossa vestibular neurotomy as primary surgical treatment of Meniere’s disease: a re-evaluation. J Laryngol Otol 2002; 116:593–596.PubMedCrossRefGoogle Scholar
  2. 2.
    Welling DH et al. Endolymphatic mastoid shunt: a reevalutation of efficacy. Otolaryngol Head Surg 2000; 122:340–345.Google Scholar
  3. 3.
    Yetiser S et al. Intratympanic gentamicin in Meniere’s disease: the impact on tinnitus. Int J Audiol 2002; 41:363–70).PubMedCrossRefGoogle Scholar

Literatur

  1. 1.
    Preston-Martin S (1990). Descriptive epidemiology of primary tumors of the spinal cord and spinal meninges in Los Angeles county, 1972–1985. Neuroepidemiol 9:106–111.Google Scholar

Literatur

  1. 1.
    Kondziolka D, Levy EI, Niranjan A et al. (1999) Long-term outcomes after meningioma radiosurgery: physician and patient perspectives. J Neurosurg 91:44–50.PubMedGoogle Scholar
  2. 2.
    Debus J, Wuendrich M, Pirzkall A (2001). High efficacy of fractionated stereotactic radiotherapy of large base-of-skull meningiomas: long-term results. J Clin Oncol 19:3547–53.PubMedGoogle Scholar
  3. 3.
    Schrell U, Rittig MH, Anders M et al. (1997) Hydroxyurea for treatment of unresectable and recurrent meningingiomas. J Neurosurg 86:840–44.PubMedGoogle Scholar

Literatur

  1. Dexamethasone in Adults with Bacterial Meningitis. J. de Gans, D. van de Beek. NEJM 347:1549–1556, Nov 2002PubMedGoogle Scholar

Literatur

  1. 1.
    Kilburn P (1957) Meralgia paraesthetica. Lancet II: 952.Google Scholar

Literatur

  1. 1.
    Gorson KC, Ropper AH, Weinberg DH, Weinstein R (2002). Efficacy of intravenous immunoglobulin in patients with IgG monoclonal gammopathy and polyneuropathy. Arch Neurol 59(5):766–772.PubMedCrossRefGoogle Scholar
  2. 2.
    Kelly JJ Jr, Adelman LS, Berkhman E, Bhan I (1988). Polyneuropathy associated with IgM monoclonal gammopathies. Arch Neurol 45:1355–1359.PubMedGoogle Scholar
  3. 3.
    Kyle RA, Dyck PJ (1993). Neuropathy associated with the monoclonal gammopathies. In: Dyck PJ, Thomas PK (Hrsg.) Peripheral Neuropathy. Saunders Philadelphia, Pennsylvania, 1275–1287.Google Scholar
  4. 4.
    Kyle RA, Dyck PJ (1993). Osteosclerotic myeloma (POEMS syndrome). In: Dyck PJ, Thomas PK (Hrsg.) Peripheral Neuropathy. Saunders Philadelphia, Pennsylvania, 1288–1293.Google Scholar
  5. 5.
    Leger JM, Younes-Chennoufi AB, Chassande B, et al. (1994). Human immunoglobulin treatment in multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy. J Neurol Neurosurg Psychiatry 57:46–49.PubMedGoogle Scholar
  6. 6.
    Nobile-Orazio E, Carpo M (2001). Neuropathy and monoclonal gammopathy. Curr Opin Neurol 14(5):615–620.PubMedCrossRefGoogle Scholar

Literatur

  1. 1.
    Empfehlungen der Deutschen Migräne-und Kopfschmerzgesellschaft.Google Scholar
  2. 2.
    Tfelt-Hansen P, Henry P, Mulder LJ, Schaeldewaert RG, Schoenen J, Chazot G (1995) The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 346: 923–926.PubMedGoogle Scholar
  3. 3.
    The Diclofenac-K/Sumatriptan Migraine Study Group (1999) Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. Cephalalgia19(4): 232–40.CrossRefGoogle Scholar

Literatur

  1. 1.
    Berlit P, Rakicky J (1992). The Miller Fisher syndrome. Review of the literature. J Clin Neuroophthalmol 12:57–63.PubMedGoogle Scholar
  2. 2.
    Gareth J, Parry MB (1993). Guillain-Barré syndrome. Thieme Medical Publishers, New York.Google Scholar
  3. 3.
    Fisher M (1956). An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med 255:57–65.PubMedGoogle Scholar
  4. 4.
    Vedeler CA (2000). Inflammatory neuropathies: update. Curr Opin Neurol 13:305–309.PubMedCrossRefGoogle Scholar
  5. 5.
    Willison HJ, Veitch J (1994). Immunoglobin subclass distribution and binding characteristics of anti-GQ1b antibodies in Miller Fisher syndrome. J Neuroimmunol 50:159–165.PubMedCrossRefGoogle Scholar

Literatur

  1. 1.
    Bremner JD. A double-blind comparison of Org 3770, amitryptilin and placebo in major depression. J Clin Psych 1995; 56:519–525Google Scholar
  2. 2.
    Kasper S. Clinical efficacy of mirtazapine: a review of meta-analyses of pooled date. Int Clin Psychopharmacol 1995; 10Suppl.4:25–35PubMedGoogle Scholar
  3. 3.
    Moffaert von et al. Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression. Int Clin Psychopharmacol 1995; 10:3–9PubMedGoogle Scholar
  4. 4.
    Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol. 1995; 10Suppl 4:37–45.PubMedGoogle Scholar
  5. 5.
    Timmer CJ et al. Clinical pharmacokinetics of mirtazepine. Clin Pharmacokinet 2000; 38:461–74.PubMedGoogle Scholar

Literatur

  1. 1.
    Faulds D, Balfour JA, Chrisp P, Langtry HD (1991). Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutical potential in the chemotherapy of cancer. Drugs 41:400–449.PubMedGoogle Scholar
  2. 2.
    Hartung HP, Gonsette R, König N et al. (2002) The Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. The Lancet 360:2018–25.CrossRefGoogle Scholar

Literatur

  1. 1.
    Gilon D, Buonanno FS, Joffe MM, Leavitt M, Marshall JE, Kistler JP, Levine RA (1999). Lack of evidence of an association between mitralvalve prolapse and stroke in young patients. N Engl J Med 341(1):8–13.PubMedCrossRefGoogle Scholar

Literatur

  1. 1.
    Neundörfer B (1987) Polyneuritiden und Polyneuropathien. VCH Verlagsgesellschaft, Weinheim.Google Scholar

Literatur

  1. 1.
    Greenfield J, Rea J, Ilfeld F (1984) Morton’s interdigital neuroma. Indications for treatment by local injections versus surgery. Clin Orthop 185:142–144.PubMedGoogle Scholar

Literatur

  1. 1.
    Dyck PJ (1993) Neuronal atrophy and degeneration predominantly affecting peripheral sensory and autonomic neurons. In: Dyck PJ, Thomas PK (eds) Peripheral Neuropathy. W. B. Saunders Company, Philadelphia, London, pp 1065–1093.Google Scholar

Literatur

  1. 1.
    Chaudry V, Corse AM, Cornblath DR, et al. (1993). Multifocal motor neuropathy: response to human immune globulin. Ann Neurol 33:237–242.Google Scholar
  2. 2.
    Gold R, Toyka KV (2001). Immuntherapie neurologischer Erkrankungen. Uni-Med, Bremen.Google Scholar
  3. 3.
    Elliott Jl, Pestronk A (1994). Progression of multifocal motor neuropathy during apparently successful treatment with immunglobulin. Neurology 44, 967–968.PubMedGoogle Scholar
  4. 4.
    Feldman EL, Bromberg MB, Albers JW, Pestronk A (1991). Immunosuppressive treatment in multifocal motor neuropathy. Ann Neurol 30:397–410.PubMedCrossRefGoogle Scholar
  5. 5.
    Meucci N, Cappellari A, Barbieri S, et al. (1997) Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 63:765–769.PubMedGoogle Scholar
  6. 6.
    Nobile-Orazio E (1996). Multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 60:599–603.PubMedGoogle Scholar
  7. 7.
    Nobile-Orazio E (2001). Multifocal motor neuropathy. J Neuroimmunol 115(1–2):4–18.PubMedGoogle Scholar
  8. 8.
    Pestronk A (1991). Motor neuropathies, motor neuron disorders, and antiglycolipid antibodies. Muscle & Nerve 14:927–936.Google Scholar
  9. 8.
    Pestronk A (1998). Multifocal motor neuropathy: diagnosis and treatment. Neurology 51, 22–24.Google Scholar

Literatur

  1. 1.
    IFNB Multiple Sclerosis Study Group (1993). Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. Neurology 43:655–61.Google Scholar
  2. 2.
    Jacobs LD, Cookfair DL, Rudick RA et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285–94.PubMedCrossRefGoogle Scholar
  3. 3.
    PRISMS Study Group (1998). Randomised double-blind placebo-controlled study of interferon-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498–1504.Google Scholar
  4. 4.
    IFNB Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group (1995). Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomised controlled trial. Neurology 45:1277–85.Google Scholar
  5. 5.
    European Study Group on interferon beta-1b in secondary progressive MS (1998). Placebo controlled multicentre randomised trial of interferon beta 1-b in the treatment of secondary progressive multiple sclerosis. Lancet 352:1491–7.Google Scholar
  6. 6.
    PRISMS-4 (2001). Long-term efficacy of interferon beta-1a in relapsing MS. Neurology 56:1628–36.Google Scholar
  7. 7.
    Jacobs LD, Beck RW, Simon JH et al and the CHAMPS Study Group (2000). Intramuscular interferon beta-1a therapy initiated during the first demyelinating event in multiple sclerosis. N Engl J Med 343:898–904.PubMedCrossRefGoogle Scholar
  8. 8.
    Johnson KP, Brooks BR, Cohen JA et al. (1995) Copolymer-1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 45:1268–76.PubMedGoogle Scholar
  9. 9.
    SPECTRIMS Study Group, Secondary Progressive Efficacy Trial of Recombinant Interferon beta-1a in MS (2001). Randomised controlled trial of Interferon beta-1a in secondary progressive MS: clinical results. Neurology 56:1496–504.Google Scholar
  10. 10.
    Hartung HP, Gonsette R, König N et al. The Mitoxantrone in Multiple Sclerosis Study Group (MIMS) (2002). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, doubleblind, randomised, multicentre trial. Lancet 360:2018–25.PubMedCrossRefGoogle Scholar
  11. 11.
    Wiendl H, Lehmann HC, Hohlfeld R, Hartung HP, Kieseier BC (2003) Immunmodulierende Therapiestrategien bei der multiplen Sklerose. Akt Neurol 30:433–441.Google Scholar

Literatur

  1. 1.
    Hoffmann F (2002). Symptomatische Therapie. In: Schmidt RM, Hoffmann F (Hrsg.) Multiple Sklerose. Urban & Fischer München-Jena. S. 182–236.Google Scholar
  2. 2.
    Netz J, Hömberg V (2001). Ergotherapie bei Multipler Sklerose. In: Zettl UK, Mix E. Multiple Sklerose. Kausalorientiert, symptomatische und rehabilitative Therapie. Springer-Verlag, Berlin New York, S. 317–323.Google Scholar
  3. 3.
    Petajan HJ, Grappmair E, White AT et al. (1996) Impact of aerobic training for fitness und quality life in multiple sclerosis. Ann Neurol 39:432–441.PubMedCrossRefGoogle Scholar

Literatur

  1. 1.
    Keegan M, Pineda A, McClelland R (2002). Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 58:143–146.PubMedGoogle Scholar
  2. 2.
    MS-Therapie Konsensus Gruppe (2002). Immunmodulatorische Stufentherapie der Multiplen Sklerose: Neue Aspekte und praktische Umsetzung, März 2002. Nervenarzt 73:556–563.Google Scholar
  3. 3.
    Oliveri R, Valentino P, Russo C et al. (1998) Randomized trial comparing two different high doses of methylprednisolone in MS. Neurology 50:1833–1836.PubMedGoogle Scholar
  4. 4.
    Weinshenker B, O’Brien P, Petterson T et al. (1999) A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 46:878–886.PubMedCrossRefGoogle Scholar

Literatur

  1. 1.
    Achiron A, Ziv I, Djadetti R et al. (1992) Aphasia in multiple sclerosis: clinical and radiologic correlations. Neurology 42:2195–2197.PubMedGoogle Scholar
  2. 2.
    Hartelius I, Runmarker B Andersen O (2000). Prevalence and characteristics of dysarthria in a multiple sclerosis incidence cohort: relation to neurological data. Folia Phoniatr Logop 52:160–177.PubMedGoogle Scholar
  3. 3.
    Schönle PW (2001). Logopädie bei Multipler Sklerose. In: Zettl UK, Mix E. Multiple Sklerose. Kausalorientiert, symptomatische und rehabilitative Therapie. Springer-Verlag, Berlin New York. S. 317–323.Google Scholar

Literatur

  1. 1.
    Alusi SH, Worthington J, Glickmann S et al. (2001). A study of tremor in multiple sclerosis. Brain 124:720–730.PubMedGoogle Scholar
  2. 2.
    Dettmers C (2001). Wohnortnahe Rehabilitation bei Multipler Sklerose. In: Zettl UK, Mix E. Multiple Sklerose. Springer-Verlag, Berlin New York. S. 293–305.Google Scholar
  3. 3.
    Pöllmann W, Albrecht H, Wötzel C et al. (2001) Physiotherapie bei der Multiplen Sklerose. In: Zettl UK, Mix E. Multiple Sklerose. Springer-Verlag, Berlin New York. S. 293–305.Google Scholar
  4. 4.
    Solari A, Filippini G, Gasco P et al. (1999) Physical rehabilitation has a positive effect on disability in multiple sclerosis patients. Neurology 52:57–62.PubMedGoogle Scholar
  5. 5.
    Thompson AJ (2000). The effectiveness of neurological rehabilitation in multiple sclerosis. J Rehabil Res Devel 37:455–461.Google Scholar
  6. 6.
    Thompson AJ (2002). Progress in neurorehabilitation in multiple sclerosis. Curr Opin Neurol 15:267–270.PubMedCrossRefGoogle Scholar
  7. 7.
    Wiles CM, Newcombe RG, Fuller KJ et al. (2001) Controlled randomised crossover trial of the effects of physiotherapy on mobility in chronic multiple sclerosis. J Neurol Neurosurg Psychiatry 70:174–179.PubMedCrossRefGoogle Scholar
  8. 8.
    Wötzel C, Wehner C, Pöllmann W et al. (2000) Therapie der Multiplen Sklerose. Ein interdisziplinäres Behandlungskonzept. 2. Aufl. Pflaum, München.Google Scholar

Literatur

  1. 1.
    McDonald W, Compston A, Edan G, Goodkin D, Hartung H, Lublin F (2001). Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121–127.PubMedCrossRefGoogle Scholar
  2. 2.
    MS-Therapie Konsensus Gruppe (2002). Immunmodulatorische Stufentherapie der Multiplen Sklerose: Neue Aspekte und praktische Umsetzung, März 2002. Nervenarzt 73:556–563.Google Scholar

Literatur

  1. 1.
    Kaufman DI, Trobe JD, Eggenberger ER et al. (2000) Practice parameter: The role of corticosteroids in the management of acute monosymptomatic optic neuritis. Neurology 54:2039–2044.PubMedGoogle Scholar
  2. 2.
    MS-Therapie Konsensus Gruppe (2002). Immunmodulatorische Stufentherapie der Multiplen Sklerose: Neue Aspekte und praktische Umsetzung, März 2002. Nervenarzt 73:556–563Google Scholar
  3. 3.
    Sellebjerg F, Nielsen H, Frederiksen J et al. (1999) A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology 52:1479–1484.PubMedGoogle Scholar

Literatur

  1. 1.
    Barkhof F, Filippi M, Miller D et al. (1997) Comparision of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120:2059–2069.PubMedCrossRefGoogle Scholar
  2. 2.
    McDonald W, Compston A, Edan G, Goodkin D, Hartung H, Lublin F (2001). Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121–127.PubMedCrossRefGoogle Scholar
  3. 3.
    Poser CM, Paty DW, Scheinberg L et al. (1983) New diagostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227–231.PubMedGoogle Scholar
  4. 4.
    Thompson A, Montalban X, Barkhof F et al. (2000) Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol 47: 831–835.PubMedCrossRefGoogle Scholar
  5. 5.
    Tintore M, Rovira A, Martinez M et al. (2000) Isolated demyelinating syndromes: comparison of different MR imaging critieria to predict conversion to clinically definite multiple sclerosis. Am J Neuroradiol 21:702–706.PubMedGoogle Scholar

Literatur

  1. 1.
    Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ, et al. (1999) Consensus statement on the diagnosis of multiple system atrophy [see comments]. J Neurol Sci 163: 94–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Graham JG, Oppenheimer DR (1969). Orthostatic hypotension and nicot sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiat 32: 28–34.PubMedCrossRefGoogle Scholar
  3. 3.
    Quinn N (1989). Multiple system atrophy-the nature of the beast. J Neurol Psychiat Suppl 52:78–89.Google Scholar
  4. 4.
    Wenning GK, Quinn NP (1994). Multisystematrophy. Ann Neurol 21: 120–126.Google Scholar
  5. 5.
    Wenning und Quinn 1994Google Scholar

Literatur

  1. 1.
    Gross et al. (1998) The treatment of severe hyponatremia. Kidney Int Suppl. 64: 6–11.Google Scholar

Literatur

  1. 1.
    Wagner et al. (1991) Ann. Nutr. Metab 35:297–302.PubMedCrossRefGoogle Scholar

Literatur

  1. 1.
    Benecke R (1996). Myoklonus, myoklonische Syndrome und ihre assozierten Erkrankungen. In: Conrad B, Ceballos-Baumann AO (Hrsg.) Bewegungsstörungen in der Neurologie. Thieme, Stuttgart 199–221.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Personalised recommendations